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Retinopathy of prematurity (ROP) is a preventable cause of visual 
impairment in premature neonates.[1] Screening and early treatment 
are important to prevent related morbidity. An increase in ROP 
has been reported in middle-income countries, as greater numbers 
of premature infants survive as a result of improved neonatal 
care, but lack adequately monitored oxygen therapy.[2] The ROP 
Working Group of South Africa (SA) has recommended guidelines 
for the prevention, screening and treatment of ROP for SA, 
based on international guidelines.[3] The United South African 
Neonatal Association, the Ophthalmological Society of South 
Africa and the South African Vitreoretinal Society have endorsed 
these recommendations, but resource limitations are acknowledged 
as a limiting factor in implementation of these guidelines.
The neonatal unit at Groote Schuur Hospital (GSH), Cape Town, 
SA, provides tertiary care for >500 very low-birth-weight (VLBW) 
and extremely low-birth-weight (ELBW) premature infants from 
the West Metro region of the Western Cape Province per year. A 
study at GSH in 1991 by Straker and Van der Elst,[4] as well as an 
unpublished study in 2001 (J C Richards, ‘Prospective evaluation of 
retinopathy of prematurity screening policy for neonatal units allied 
to the University of Cape Town’), did not detect any ROP requiring 
treatment. Based on these findings and resource constraints, an ROP 
screening service was not instituted.
More recent data from other tertiary SA hospitals suggested that 
a review is required. Studies between 1995 and 2013 reported a 
prevalence of ROP ranging from 16.3% to 31.1%.[5-8] The prevalence 
of severe ROP ranged from 4.3% to 7.1%, with no infant weighing 
>1 250 g requiring treatment. These studies all reported infants 
requiring treatment for ROP. Based on these data, we secured funding 
to conduct a 6-month pilot study.  The objectives of the study were 
to: (i) determine the prevalence and severity of ROP in a prospective 
cohort of preterm infants; (ii) describe the association of prespecified 
potential risk factors; and (iii) assess the feasibility of screening for 
ROP in a relatively resource-limited setting.
Methods
A prospective cohort study of a pilot ROP screening programme was 
conducted at GSH from November 2012 to May 2013. This study 
was approved by the Human Research Ethics Committee, Faculty of 
Health Sciences, University of Cape Town (HREC/REF: 509/2012) 
and conformed to the principles of the 2013 Declaration of Helsinki.[9]
Inclusion criteria for screening were a birth weight (BW) of 
<1 251 g or birth gestational age (GA), confirmed by a Ballard score, of 
≤31 weeks at birth. Patients with lethal congenital conditions or those 
whose parents refused consent for screening were excluded. Written 
informed parental consent was obtained for ROP examination and 
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inclusion into the study. Consent was obtained from the medical 
superintendent for infants being fostered or adopted.
Medical management
The 2010 International Liaison Committee on Resuscitation 
guideline[10] was followed. Infants were monitored with pulse 
oximetry, targeting saturations of 88 - 92%. Exclusive breastmilk 
feeds were encouraged for all infants, donor breastmilk being variably 
available to infants weighing <1 200 g. Cranial ultrasound scans were 
performed in the first week of life and repeated at discharge, or earlier 
if indicated.
Screening ophthalmic examination
A paediatric ophthalmologist examined infants once a week. The 
neonatal unit’s admissions book was reviewed daily to identify 
eligible infants. A register and diary were kept to facilitate the 
timing of examinations. The first examination occurred at 4  weeks’ 
chronological age or at 32 weeks’ corrected GA, whichever occurred 
later. Examination was deferred in clinically unstable infants. A 
research assistant was employed for the duration of the study to 
complete administration and assist during examinations. Combination 
cyclopentolate hydrochloride and phenylephrine hydrochloride drops, 
one drop every 15 minutes up to a maximum of three, were instilled 
into each eye in preparation for screening. Benoxinate hydrochloride 
0.4% was used as a local anaesthetic. Inpatients were monitored as per 
standard practice in the neonatal unit. Outpatients were discharged 
once they had been successfully fed after the examination. The 
infants’ retinas were examined by binocular indirect ophthalmoscopy. 
The ophthalmologist determined follow-up according to standard 
guidelines.[11]
If infants were transferred, receiving hospitals were informed that 
screening needed to be completed. On discharge, appointments were 
communicated to parents and documented. As a reminder, both 
receiving hospitals and outpatients were contacted by telephone 
3 days prior to appointments. If three consecutive appointments were 
missed, no further contact was attempted. However, if the research 
assistant was contacted, a booking was made for the next session.
Infants were discharged from screening according to recom-
mended SA guidelines.[3] Initial and subsequent follow-up was done 
at the GSH neonatal unit. Infants requiring prolonged follow-up 
were reviewed at the ophthalmology outpatient clinic at Red Cross 
War Memorial Children’s Hospital, Cape Town. A maximum of 
20 patients were examined per session.
Treatment of ROP
Treatment was administered according to the Early Treatment for 
Retinopathy of Prematurity Randomized Trial guidelines.[12] A retinal 
specialist performed laser treatment in the neonatal unit within 
72 hours of diagnosis.
Data collection and statistical analysis
Data collected included demographic details as well as clinical 
information such as the occurrence of early (<72 hours after delivery) 
or late (≥72 hours after delivery) onset of sepsis, intraventricular/
periventricular haemorrhage (grade 3 or 4), and type of enteral 
nutrition received in the first 6 weeks of life.
Findings of screening examination were recorded, including the 
presence or absence of ROP, grade of ROP if present (International 
Classification of Retinopathy of Prematurity revisited[13]), findings at 
follow-up examination and the need for ROP treatment.
Stata version 12 (StataCorp, USA) was used for statistical analysis. 
Demographic and clinical data were presented with descriptive 
statistical methods. Comparative statistical analysis was done on 
infants grouped according to the presence of ROP v. infants with no 
ROP as a primary outcome. Further analysis was done to compare 
infants with no or only mild ROP with those who had clinically 
significant ROP (CSROP). The presence of stage 3 ROP or any stage 
of ROP with plus disease was classified as CSROP.
Factors associated with different grades of severity were described. 
The χ2 test or Fisher’s exact test was used for categorical comparisons, 
depending on the expected values. Student’s t-test and the Wilcoxon 
rank-sum test were used for comparison of parametric and non-
parametric continuous variables, respectively. All statistical tests 
were two-sided at alpha = 0.05. Multivariate analysis was performed 
on statistically significant risk factors (p<0.2). Multivariate analysis 
was done using a Poisson regression model with a robust error 
variance for relative risk.
Results
Screening was performed in 135 of the 191 eligible infants. Fig. 1 
shows the derivation of the final dataset. The prespecified perinatal 
characteristics of the cohort are shown in Table 1. The mean GA 
and BW were 30.1 weeks (standard deviation (SD) 1.9) and 1 056 g 
(SD  172), respectively. Seventy-four infants (54.8%) were female. 
Only black (57.1%) and coloured (42.9%) infants were represented in 
the sample. One infant had a family history of ROP.
In total, 313 examinations were performed; 38.5% of infants 
required one, 31.9% two and 16.3% four or more examinations. 
Three infants (2.2%) had eight ROP examinations.
ROP was diagnosed in 40 infants (29.6%); 8 (5.9%) had CSROP. No 
infant had stage 4 or 5 ROP. Stage 3 ROP occurred in only one infant 
with a BW >1 250 g, but regressed and did not require treatment. 
Two  infants received laser treatment. Screening was completed in 
91.1% (123/135). Twelve infants were lost to follow-up. Of these, 7 
(58.3%) had ROP and 2 (16.7%) had CSROP.
Table 2 shows comparisons of prespecified potential risk factors. 
Infants with ROP had a lower mean GA and BW than those without 
ROP: 29.2 weeks (SD 1.6) v. 30.5 weeks (SD 1.9) (p<0.002) and 988 g 
(SD 181) v. 1 085 g (SD 160) (p=0.001), respectively. Infants with 
ROP were more likely than those without to have received a blood 
transfusion (p<0.002) (Fig. 2), to have late-onset sepsis (p=0.024) 
(Fig. 3), and to have received exclusive breastmilk feeds (p=0.005).
There were no statistically significant differences in potential risk 
factor exposure in infants with mild ROP or CSROP. A comparison 
of potential risk factors between infants with CSROP and those with 
either mild ROP or no ROP (Table 2) showed that infants delivered 
via caesarean section were less likely to develop CSROP (p=0.007).
On multivariate analysis, GA at birth was the only variable 
independently associated with ROP (risk ratio (RR) 0.85, 95% confi-
dence interval (CI) 0.740 - 0.988; p=0.03). If GA was excluded, BW 
(RR 0.99, 95% CI 0.997 - 0.999; p=0.03) and blood transfusions 
(RR  1.71, 95% CI 1.027 - 2.859; p=0.03) were independently asso-
ciated with ROP. ELBW infants had a 2.5 times higher risk of having 
ROP than infants with a BW ≥1 000 g (95% CI 1.05 - 5.90; p=0.03). 
The prevalence of ROP according to BW is described further in Fig. 4.
Discussion
ROP occurred in 29.6% of the study cohort; 5.9% developed CSROP 
and 2 (1.5%) received laser treatment. Infants who required treatment 
weighed <1 250 g at birth. This prevalence is significantly higher 
than in previous studies at GSH.[4,5] Infrastructure and resources 
in the healthcare facilities referring to GSH have improved in the 
past two decades. Additionally, surfactant therapy and non-invasive 
ventilation are more accessible, contributing to improved preterm 
(n=12)
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survival.[14] Straker and Van der Elst[4] reported a prevalence of ROP 
of 19.2%, including all infants with a BW of <1 500 g; 1.5% of infants 
developed severe ROP and no infant required treatment. However, 
infants in their study were small for GA. The lower weight inclusion 
Table I. Perinatal characteristics of the cohort (N=135)
Infant characteristics
BW (g), mean (SD) 1 056 (172)
GA (wk), mean (SD) 30.1 (1.9)
Racial group, n (%) 
Black 77 (57.0)
Coloured 58 (43.0)
Female gender, n (%) 74 (54.8)
Family history of ROP, n (%) 1 (0.7)
Maternal history, n (%)
Mother VDRL-positive 2 (1.5)
Mother HIV-positive 22 (16.3)
Maternal medication use 58 (43.0)
Cigarettes/tik/alcohol use 16 (11.9)
Illness 73 (54.9)
Birth and resuscitation history
Outborn, n (%) 10 (7.4)
Mode of delivery CS, n (%) 95 (71.1)
Apgar score (N=133), median (IQR)
1 min 7 (4 - 8)
5 min 9 (7 - 9)
Resuscitation required (N=131), n (%) 85 (64.9)
Oxygen administered 103 (76.3)
Facemask/T-piece ventilation (N=131), n (%) 85 (64.9)
Endotracheal intubation (N=131), n (%) 13 (9.9)
Chest compressions (N=131), n (%) 26 (19.9)
Neonatal period
Respiratory support 
O2 therapy, n (%) 122 (90.4)
CPAP/HHFNC/nasal cannula O2, n (%) 95 (70.4)
Mechanical ventilation, n (%) 27 (20.0)
 Duration of O2 therapy (days), median 
(IQR)
5 (2 - 10)
 Highest concentration of O2 received, 
median (IQR)
0.3 (0.25 - 
0.37)
Surfactant, n (%) 40 (29.6)
Apnoea, n (%) 37 (27.4)
Blood transfusion, n (%) 28 (20.7)
Sepsis, n (%)
Early 1 (0.7)
Late 7 (5.2)
IVH (grade 3 or 4) (N=132), n (%) 4 (3.0)
Exclusive breastmilk feeds, n (%) 50 (37.0)
VDRL = Venereal Disease Research Laboratory; tik = methamphetamine; CS = caesarean 
section; IQR = interquartile range; CPAP = continuous positive airway pressure; 
HHFNC = humidified high-flow nasal cannula; IVH = intraventricular haemorrhage.
Met screening criteria (N=191)
Died before screening (n=48)
Refused consent/missed opportunity (n=2)
Consented (n=141)
Transferred to a private facility (n=1)
Defaulted screening visit (n=5)
Attended screening visit (n=135)
Defaulted after one or more visits (n=12)
Complete data for all 
required visits (n=123)
Fig. 1. Derivation of the final data set.
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Fig. 2. Prevalence of ROP in infants receiving blood transfusions (N=135).
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Fig. 3. Prevalence of ROP in infants with late-onset sepsis (N=135).
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criteria in our study, with a potentially greater proportion of less 
mature infants being included, may explain the higher prevalence 
of ROP. Growth restriction was not specifically assessed. Richards 
(unpublished data) reported an overall ROP prevalence of 3.6% 
in infants weighing <1 500 g, increasing to 14.5% in the subgroup 
of <28 weeks’ GA at birth, with no infant requiring treatment. 
However, infants were assessed at 6 weeks’ chronological age and then 
again at term if no ROP was initially detected, potentially missing 
infants who developed ROP that then regressed before review. 
Repeat examinations in our study occurred more frequently, every 
2 - 3 weeks. In Richards’ unpublished study, 73% of infants attended 
follow-up, but only 44% of infants of <28 weeks’ GA were seen more 
than once. The higher rate of ROP in our study may be due to the 
higher proportion attending follow-up.
Other SA studies show a significant prevalence of ROP. In 1997, 
Gilbert et al.[14] found that ROP accounted for 10.6% of blindness. 
In 1995, Kirsten et al.[7] showed a 31.1% prevalence of ROP in 
mechanically ventilated VLBW infants, with 7.1% stage 3 or worse 
ROP, probably owing to the exclusive inclusion of mechanically 
ventilated infants. In 2002, Delport et al.[6] found a prevalence of ROP 
of 24.5% in VLBW infants at Kalafong Hospital, Pretoria, SA. Only 
two infants with a BW of >1 250 g developed ROP, similar to our 
findings. The prevalence of severe ROP was 3.2% in infants weighing 
<1 250 g at birth, with 4.3% requiring treatment, slightly higher than 
in our study. In a study in Johannesburg published in 2006, Mayet 
et al.[5] showed a 16.3% prevalence of ROP in VLBW infants – 1.6% 
of infants received treatment. As in other SA studies, the majority 
of infants with ROP weighed <1 250_g and no infant weighing 
>1 250 g required treatment. The higher follow-up rate in our study 
may account for the apparent higher ROP prevalence. A study at 
Tygerberg Hospital, Cape Town, published in 2013,[8] reported an 
ROP prevalence of 21.8% in ELBW infants, with 4.4% of infants 
developing CSROP. The proportion of infants needing treatment 
was the same as in our study. Although the BW and GA criteria were 
lower than the inclusion criteria we used, the prevalences of ROP and 
CSROP were significantly lower, possibly because of the exclusion of 
infants mechanically ventilated in the first week of life.
Infants in our study with ROP had a lower mean GA and mean 
BW than those without, similar to other SA and certain middle-
income country studies.[2,6,7,10,15,16] On multivariate analysis, only GA 
was independently associated with ROP; however, GA assessment 
may be inaccurate as it was based on antenatal ultrasound scans, 
which often occurred only after 20 weeks’ gestation, and/or the 
Ballard score, which is only accurate to ±2 weeks. When GA is 
removed from the analysis, lower BW remains an independent risk 
factor for ROP.
Infants with ROP were more likely than those without to have 
received a blood transfusion and, as in other studies, to have late 
onset-sepsis.[16] Small numbers of these patients, owing to restrictive 
transfusion policies and a low incidence of sepsis, prevented 
meaningful interpretation of their risk of developing CSROP.
In contrast to other studies citing a protective role or no effect 
of feeding with breastmilk,[17-19] infants in our study who received 
exclusive breastmilk feeds were more likely to have ROP. Unit 
policy at the time restricted the use of donor breastmilk feeds to 
infants weighing <1 200 g.  The use of exclusive breastmilk feeding 
was therefore associated with lower BW, which may have been a 
confounder in this finding.
Previous studies have found a low occurrence of severe ROP in 
black infants or those with darkly pigmented fundi.[6,20] Interpretation 
of this risk factor was not possible, as only black and coloured 
infants were represented in our cohort. Genetics may play a role in 
developing ROP.[21] Only one infant in our study had a family history 
of ROP, which probably reflects the lack of ROP screening services 
in the public health sector. There were no significant differences in 
maternal risk factors, place of birth, mode of delivery or need for 
resuscitation between the groups with and without ROP.
The level of respiratory support, the need for oxygen therapy, 
and the occurrence of apnoea, early sepsis or severe intraventricular 
haemorrhage were also similar between infants with and without 
ROP.
The role of oxygen has been well described in the development of 
ROP.[1] No statistical significance was found when comparing oxygen 
concentration and duration of oxygen received in the two groups. 
This finding may be due to strict saturation targeting in infants 
receiving oxygen therapy. One infant who had never received oxygen 
therapy developed ROP, implying that prematurity may be a more 
significant factor than exposure to oxygen therapy.[22]
When analysing risk factors in infants with mild/no ROP and 
CSROP, infants delivered via caesarean section were less likely to 
have CSROP. The association could be related to the potential for 
greater exposure to both hypoxia and hyperoxia in vaginal deliveries. 
Moreover, pre-eclamptic toxaemia (PET) may increase the likelihood 
of delivery via caesarean section. A negative correlation between 
ROP and PET has been described.[23] The association of delivery 
via caesarean section and a decreased prevalence of ROP may be 
a chance one. The small numbers in our study precluded further 
analysis.
Successful ROP screening required extensive resources. A research 
assistant was employed to assist with administrative tasks, in 
preparation for screening and during examination. ROP examination 
was only available at GSH, which posed the potential problem 
of overcrowding with the associated risks. If patients had been 
transferred to step-down facilities, availability of ambulance services 
and accommodation in a tertiary service with limited bed capacity 
when transfer back for ROP examination was required would have 
posed challenges. Outpatient facilities, staffing and equipment had 
to be provided when infants were discharged before completion of 
screening.
Laser treatment was performed in the neonatal unit within 
72  hours of diagnosis for infants requiring treatment. Challenges 
included the provision of theatre facilities in the neonatal unit, 
equipment and staffing, including the availability of a retinal surgeon. 
Centralised care must be considered when infants require treatment 
for ROP. Theatre facilities need to accommodate the specific needs 
of preterm infants. Facilities for treatment, in addition to skilled 
clinicians for ophthalmic examination and treatment of ROP, should 
be available before embarking on a screening programme.
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Fig. 4. Prevalence of ROP in BW categories (N=135).
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Table 2. Potential risk factors for the development of ROP (N=135)
Potential risk factors
No ROP
(N=95)
ROP
(N=40) p-value
No or mild ROP 
(N=127)
CSROP
(N=8) p-value
Infant characteristics
BW (g), mean (SD) 1 084 160) 988 931) 0.002 1 059 (172) 1 006 (171) 0.391
GA (wk), mean (SD) 30.5 1.9) 29.2 1.6) <0.001 30.2 (1.9) 29.4 (1.3) 0.260
Racial group, n (%) 0.146 0.074*
Black 58 (61.0) 19 (47.5) 75 (59.1) 2 (25.0)
Coloured 37 (39.0) 21 (52.5) 52 (40.9) 6 (75.0)
Female gender, n (%) 50 (52.6) 24 (60.0) 0.432 70 (55.1) 4 (50.0) 1.000*
Family history of ROP, n (%) 0 (0.0) 1 (2.5) 0.296* 1 (0.8) 0 (0.0) 1.000*
Maternal history, n (%)
Mother VDRL-positive 1 (1.1) 1 (2.5) 0.506* 2 (1.6) 0 (0.0) 1.000*
Mother HIV-positive 15 (15.8) 7 (17.5) 0.806 21 (16.5) 1 (12.5) 1.000*
Maternal medication use 39 (41.1) 19 (47.5) 0.490 56 (44.1) 2 (25.0) 0.466*
Cigarettes/tik/alcohol use 10 (10.5) 6 (15.0) 0.377* 14 (11.1) 2 (25.0) 0.292*
Illness 51 (54.3) 22 (56.4) 0.820 71 (56.8) 2 (25.0) 0.140*
Birth and resuscitation history
Outborn, n (%) 7 (7.4) 3 (7.5) 1.000* 9 (7.1) 1 (12.5) 0.469*
Mode of delivery CS 73 (76.8) 23 (57.5) 0.024 94 (74.1) 2 (25.0) 0.007*
Apgar score (N=133), median (IQR)
1 min 7 (4 - 8) 7 (3 - 8) 0.796† 7 (4 - 8) 7 (3 - 9) 0.833†
5 min 9 (7 - 9) 9 (7 - 9) 0.775† 9 (7 - 9) 9 (6 - 10) 0.661†
 Resuscitation required (N=131), 
n (%)
61 (66.3) 24 (61.5) 0.601 81 (63.8) 4 (50.0) 0.571*
Oxygen administered, n (%) 74 (77.9) 29 (72.5) 0.501 98 (77.2) 5 (62.5) 0.394*
 Facemask/T-piece ventilation 
(N=131), n (%)
61 (66.3) 24 (61.5) 0.601 81 (63.8) 4 (50.0) 0.571*
 Endotracheal intubation (N=131), 
n (%)
6 (6.3) 7 (17.5) 0.132 12 (9.5) 1 (12.5) 0.670*
Chest compressions (N=131), n (%) 15 (15.8) 11 (27.5) 0.288 23 (18.1) 3 (37.5) 0.371*
Neonatal period
Respiratory support
O2 therapy, n (%) 85 (89.5) 37 (92.5) 0.755* 115 (90.5) 7 (87.5) 0.565*
 CPAP/HHFNC/nasal cannula O2, 
n (%)
66 (69.5) 29 (72.5) 0.725 88 (69.3) 7 (87.5) 0.435*
Mechanical ventilation, n (%) 19 (20.0) 8 (20.0) 1.000* 27 (21.3) 0 (0.0) 0.357*
 Duration of O2 therapy (days), 
median (IQR)
4 (2 - 8) 5.5 (2 - 14) 0.360† 5 (2 - 10) 9 (4 - 10) 0.418†
 Highest concentration of O2 
received (N=122), median (IQR)
0.3 (0.25 - 0.4) 0.3 (0.25 - 0.35) 0.859† 0.3 (0.25 - 0.38) 0.3 (0.3 - 0.35) 0.582†
Surfactant, n (%) 27 (28.4) 13 (32.5) 0.636 38 (29.9) 2 (25.0) 1.000*
Apnoea, n (%) 24 (25.3) 13 (32.5) 0.389 33 (26.0) 4 (50.0) 0.214*
Blood transfusion, n (%) 12 (12.6) 16 (40.0) <0.001 26 (20.5) 2 (25.0) 0.670*
Sepsis, n (%)
Early 0 (0.0) 1 (2.5) 0.122 1 (0.8) 0 (0.0) 1.000*
Late 2 (2.1) 5 (12.5) 0.024* 6 (4.7) 1 (12.5) 0.355*
IVH (grade 3 or 4) (N=132), n (%) 4 (4.2) 0 (0.0) 0.553* 4 (3.2) 0 (0.0) 1.000*
Breastmilk feeds, n (%) 28 (29.5) 22 (55.0) 0.014* 46 (36.2) 4 (50.0) 0.534*
VDRL = Venereal Disease Research Laboratory; tik = methamphetamine; CS = caesarean section; IQR = interquartile range; CPAP = continuous positive airway pressure; HHFNC = humidified 
high-flow nasal cannula; IVH = intraventricular haemorrhage.
*Fisher’s exact test.
†Wilcoxon rank-sum test.
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The follow-up rate in this study was 91.1%. Study funding ensured 
that resources were allocated to facilitate this. Parents were well 
informed, were aware of follow-up appointments and were contacted 
when appointments were missed. Transport costs were reimbursed if 
required. Despite this, 12 infants were lost to follow-up, including 2 
with CSROP. The loss to follow-up rate is similar to that of Van der 
Merwe et al.,[8] (13.8%), significantly lower than in other SA studies.  
Strengths of our study were the high enrolment and follow-up 
rates, which support the validity of the sample. All screening was 
performed by two paediatric ophthalmologists, ensuring consistency 
in reporting and management of ROP findings. Limitations of the 
study were the potential inaccuracy of GA assessment, questioning 
the use of this parameter in clinical guidelines for screening. 
Additionally, not all race groups were represented in the study 
population. Although the prevalence of ROP is similar to those in 
other SA studies, it might have been different if all race groups had 
been represented in the sample.
Innovative technologies may help to compensate for resource 
constraints for ROP screening. Retcams present a cost-effective 
solution with which retinal images can be obtained by trained non-
opthalmologists and evaluated by remote experts with high reliability 
and accuracy in detecting referral-warranted ROP.[24] Additionally, 
software that identifies infants at risk of developing severe ROP, 
such as WINROP,[25] a web-based screening tool developed at the 
University of Gothenburg in Sweden, which uses an algorithm based 
on serial weekly neonatal body weight measurements to support 
ROP risk prediction. Although the use of the software is currently 
free, limited staffing prevented us from exploring this tool.  Further 
studies comparing the prevalence of ROP in various provincial 
hospitals, possibly using retcams and WINROP, would be of value.
Conclusion
The prevalence of ROP in this study is similar to that in other 
reported SA studies, which do not reflect the ‘third epidemic’ of 
ROP. No infant weighing >1 250 g required laser treatment. The 
independent association of ROP with BW and the absence of ROP 
requiring treatment in the larger infants suggest that infants with 
lower BWs should be prioritised for screening in our resource-
limited setting. It was feasible to screen for ROP using the criteria 
in our study, but additional funded nursing and administrative 
assistance, skilled personnel, laser treatment, theatre facilities within 
or outside the neonatal unit and neonatal intensive care had to be 
readily accessible to infants requiring treatment. ROP screening has 
been implemented at GSH based on the study findings. If broader 
screening criteria were applied, further resources would need to be 
made available. However, if appropriate oxygen targets are in place, 
the yield of ROP requiring treatment in larger and/or more mature 
infants is likely to be very low.
1. Bedrossian RH, Carmichael P, Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. 
I. Clinical study. II. Further observations on the disease. Am J Ophthalmol 1954;37(1):78-86.
2. Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity 
in countries with low, moderate, and high levels of development: Implications for screening programs. 
Pediatrics 2005;115(5):e518-e25. http://dx.doi.org/10.1542/peds.2004-1180
3. Visser L, Singh R, Young M, et al. Guideline for the prevention, screening and treatment of retinopathy 
of prematurity (ROP). S Afr Med J 2012;103(2):116-125. http://dx.doi.org/10.7196/samj.6305
4. Straker CA, van der Elst CW. The incidence of retinopathy of prematurity at Groote Schuur Hospital, 
Cape Town. S Afr Med J 1991;80(6):287-288.
5. Mayet I, Cockinos C. Retinopathy of prematurity in South Africans at a tertiary hospital: A prospective 
study. Eye 2006;20(1):29-31. http://dx.doi.org/10.1038/sj.eye.6701779
6. Delport SD, Swanepoel JC, Odendaal PJ, et al. Incidence of retinopathy of prematurity in very-low-
birth-weight infants born at Kalafong Hospital, Pretoria. S Afr Med J 2002;92(12):986-690.
7. Kirsten GF, van Zyl JI, le Grange M, et al. The outcome at 12 months of very-low-birth-weight infants 
ventilated at Tygerberg Hospital. S Afr Med J 1995;85(7):649-654.
8. Van der Merwe SK, Freeman N, Bekker A, et al. Prevalence of and risk factors for retinopathy of 
prematurity in a cohort of preterm infants treated exclusively with non-invasive ventilation in the first 
week after birth. S Afr Med J 2013;103(2):96-100. http://dx.doi.org/10.7196/SAMJ.6131
9. World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles 
for Medical Research Involving Human Subjects. JAMA 2013;310(20):2191-2194. http://dx.doi.
org/10.1001/jama.2013.281053
10. Perlman JM, Wyllie J, Kattwinkel J, et al. Neonatal Resuscitation: 2010 International Consensus 
on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment 
Recommendations. Pediatrics 2010;126(5):e1319-e1344. http://dx.doi.org/10.1542/peds.2010-2972B
11. Fierson MW, Flynn J, Good W, et al. Screening examination of premature infants for retinopathy of 
prematurity. Pediatrics 2006;117(2):572-576. http://dx.doi.org/10.1542/peds.2005-2749
12. Good WV, Hardy RJ, Dobson V, et al. Revised indications for the treatment of retinopathy of 
prematurity: Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch 
Ophthalmol 2003;121(12):1684-1696. http://dx.doi.org/10.1001/archopht.121.12.1684
13. Gole GA, Ells AL, Katz X, et al. The International Classification of Retinopathy of Prematurity 
revisited. Arch Ophthalmol 2005;123(7):991-999. http://dx.doi.org/10.1001/archopht.123.7.991
14. Gilbert C, Rahi J, Eckstein M, et al. Retinopathy of prematurity in middle-income countries. Lancet 
1997;350(9070):12-14. http://dx.doi.org/10.1016/S0140-6736(97)01107-0
15. Goncalves E, Nasser LS, Martelli DR, et al. Incidence and risk factors for retinopathy of prematurity 
in a Brazilian reference service. Sao Paulo Med J 2014;132(2):85-91. http://dx.doi.org/10.1590/1516-
3180.2014.1322544 
16. Hakeem AH, Mohamed GB, Othman MF. Retinopathy of prematurity: A study of prevalence and risk 
factors. Middle East Afr J Ophthalmol 2012;19(3):289-294. http://dx.doi.org/10.4103/0974-9233.97927
17. Manzoni P, Stolfi I, Pedicino R, et al. Human milk feeding prevents retinopathy of prematurity (ROP) 
in preterm VLBW neonates. Early Hum Dev 2013;89(Suppl 1):S64-S68. http://dx.doi.org/10.1016/
S0378-3782(13)70019-7
18. Hylander MA, Strobino DM, Pezzullo JC, et al. Association of human milk feedings with a reduction in 
retinopathy of prematurity among very low birthweight infants. J Perinatol 2001;21(6):356-362. http://
dx.doi.org/10.1038/sj.jp.7210548
19. Heller CD, O’Shea M, Yao Q, et al. Human milk intake and retinopathy of prematurity in extremely low 
birth weight infants. Pediatrics 2007;120(1):1-9. http://dx.doi.org/10.1542/peds.2006-1465
20. Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity: Cryotherapy for Retinopathy 
of Prematurity Cooperative Group. Arch Ophthalmol 2000;118(5):645-649. http://dx.doi.org/10.1001/
archopht.118.5.645
21. Mohamed S, Schaa K, Cooper ME, et al. Genetic contributions to the development of retinopathy of 
prematurity. Pediatr Res 2009;65(2):193-197. http://dx.doi.org/10.1203/PDR.0b013e31818d1dbd
22. Phelps DL. Retinopathy of prematurity: an estimate of vision loss in the United States – 1979. Pediatrics 
1981;67(6):924-925.
23. Yu XD, Branch DW, Karumanchi SA, et al. Preeclampsia and retinopathy of prematurity in preterm 
births. Pediatrics 2012;130(1):e101-107.
24. Salcone EM, Johnston S, VanderVeen S. Review of the use of digital imaging in retinopathy of 
prematurity screening. Semin Ophthalmol 2010;25(5-6):214-217. http://dx.doi.org/10.3109/08820538.
2010.523671
25. Lundgren P, Sjöström ES, Domellöf M, et al. WINROP identifies severe retinopathy of prematurity 
at an early stage in a nation-based cohort of extremely preterm infants. PLoS One 2013;8(9):e73256. 
http://dx.doi.org/10.1371/journal.pone.0073256
Accepted 15 August 2016.
